SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program
Dr. Favre brings extensive experience in gene therapy, immunology and drug development Appointment comes at a pivotal time of Company growth as it prepares for clinical development and expands its…
Read More
Splice Bio awarded with a “Colaboración Público-Privada” grant
BARCELONA, January 26, 2023 – SpliceBio, a genetic medicines company on a mission to expand the universe of diseases that can be addressed with gene therapy, announced today that it…
Read More
SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline
Financing co-led by UCB Ventures and Ysios Capital with participation by New Enterprise Associates, Gilde Healthcare, Novartis Venture Fund and Asabys Partners Unique Protein Splicing platform enables efficient delivery of…
Read More
Splice Bio appoints Jean-Philippe Combal as Chairman of the Board of Directors
BARCELONA, January 21, 2021 – Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has appointed Jean-Philippe Combal…
Read More
Splice Bio announces research funding by Cystic Fibrosis Foundation to develop novel AAV vectors
BARCELONA, December 10, 2020 – Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a research agreement with the Cystic Fibrosis…
Read More
Splice Bio awarded with a “RETOS de Colaboración” grant
BARCELONA, October 20, 2020 – Splice Bio, a biotech company based on technology developed in the Muir lab at Princeton University, announced today that it has been awared a “RETOS-Colaboración”…
Read More
ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio
ProteoDesign rebrands as Splice Bio to develop novel gene therapies based on its proprietary intein technology. This pioneering platform has the potential to target genetic diseases that cannot be addressed…
Read More